key: cord-0733958-k5kbrp05
authors: Romanelli, Antonio; Mascolo, Silvia
title: Immunosuppression drug‐related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis
date: 2020-04-15
journal: Am J Transplant
DOI: 10.1111/ajt.15905
sha: 2b463a32a405e22bfc52ba3f4f291809f9207c77
doc_id: 733958
cord_uid: k5kbrp05

We read with interest the article of Guillen et al. 1 . Here, the authors described the management of a kidney transplanted patient infected by SARS-CoV-2 that causes novel Coronavirus disease 2019 (COVID-19). The authors stated that immunosuppressed patients might present with atypical clinical manifestation (fever, diarrhea, fatigue) without respiratory symptoms. Also Li and colleagues 2 reported SARS-CoV-2 infection in two solid organ transplanted patients. The two heart transplanted patients presented with variable severity of COVID-19 (one mild and another with more severe manifestations requiring a prolonged hospitalization), however, both survived the event.

To the Editor:

We read with interest the article of Guillen et al. 1 Here, the authors described the management of a kidney transplanted patient in- Actually, except for the case reports mentioned above, we found no data about the incidence and outcome of COVID-19 in this cluster of patients. Furthermore, immunosuppressive drugs could be a valid "therapeutic" choice, reducing the activity of the T cell immune system and preventing organ injury.

Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation?

First cases of COVID-19 in heart transplantation from China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

COVID-19: yet another coronavirus challenge

Impact of mycophenolic acid and tacrolimus on Th17-related immune response